Arca
Skip to content
Tools
Tools

Obesity Drug Race

Drugs like Wegovy and Zepbound changed how obesity is treated, and dozens of companies are racing to follow. See every weight-loss drug in trials, how far each has got, and which are already approved.

Drug programs in 926 company-run obesity and overweight trials that started since 2018, from ClinicalTrials.gov. One row per drug, however the registry spells it; a drug counts as reaching a phase when its first trial in that phase starts.

  • In phase 3 or approved: 50
  • In phase 2: 75
  • FDA approved since 2018: 4

Every Obesity Drug That Reached Phase 3

Each bar starts at the drug's first obesity trial since 2018 and darkens as it starts a later phase. Hover a bar for the dates.

  • Phase 1
  • Phase 2
  • Phase 3
  • FDA approved

Every Program That Reached Phase 2

Furthest along first; a drug name opens its obesity trials on ClinicalTrials.gov.
DrugCompanyFurthestSinceTrials
Setmelanotide RM-493Rhythm PharmaceuticalsApprovedNov 25, 20203 open of 12
SemaglutideNovo NordiskApprovedJun 4, 202117 open of 63
LiraglutideNovo NordiskApprovedDec 23, 20142 open of 4
Tirzepatide LY3298176Eli LillyApprovedNov 8, 202316 open of 39
Orforglipron LY3502970Eli LillyApprovedApr 1, 202612 open of 24
Recombinant Human Growth HormoneChangchun GeneScience PharmaceuticalPhase 3Apr 14, 20181, none open
DCCRSoleno TherapeuticsPhase 3May 9, 20183, none open
LorcaserinKanion & Huawe MedicinePhase 3Sep 17, 20191, none open
Aramchol free acidGalmed Research and DevelopmentPhase 3Sep 23, 20191, none open
CagrilintideNovo NordiskPhase 3Nov 1, 202213 open of 31
IBI362Innovent Biologics (Suzhou)Phase 3Nov 14, 20226 open of 13
Ecnoglutide XW003Hangzhou Sciwind BiosciencesPhase 3Apr 5, 20237 open of 9
Retatrutide LY3437943Eli LillyPhase 3May 30, 20237 open of 17
Survodutide BI 456906Boehringer Ingelheim Pharmaceuticals, Inc.Phase 3Nov 20, 20235 open of 22
TG103CSPC Baike (Shandong) BiopharmaceuticalPhase 3Nov 22, 20235, none open
HM11260CHanmi Pharmaceutical Company LimitedPhase 3Jan 3, 20241, none open
HRS9531Fujian Shengdi PharmaceuticalPhase 3May 13, 20246 open of 15
Pitolisant HBS-101Harmony Biosciences ManagementPhase 3May 28, 20242 open of 3
ARD-101Aardvark TherapeuticsPhase 3Jul 23, 20245, none open
Olatorepatide HS-20094Regeneron PharmaceuticalsPhase 3Nov 16, 20243 open of 5
Mibavademab REGN4461Regeneron PharmaceuticalsPhase 3Dec 16, 20241 open of 2
VCT220Vincentage PharmaPhase 3Dec 24, 20242 open of 8
BofanglutidaGan & Lee PharmaceuticalsPhase 3Dec 30, 20244 open of 16
Maridebart Cafraglutide AMG 133AmgenPhase 3Mar 12, 202518 open of 29
HDM1002Hangzhou Zhongmei Huadong PharmaceuticalPhase 3Mar 28, 20252 open of 5
HRS-7535Shandong Suncadia MedicinePhase 3Apr 10, 20252 open of 6
CagriSemaNovo NordiskPhase 3Jun 3, 20254 open of 5
RAY1225Guangdong Raynovent BiotechPhase 3Jun 15, 20253 open of 4
VK2735Viking TherapeuticsPhase 3Jun 23, 20254 open of 6
IN-B00009HK inno.NPhase 3Sep 22, 20251 open of 1
HDM1005Hangzhou Zhongmei Huadong PharmaceuticalPhase 3Oct 14, 20257 open of 7
Eloralintide LY3841136, LY900043Eli LillyPhase 3Dec 15, 202513 open of 20
Ribupatide KAI-9531KaileraPhase 3Dec 18, 20256 open of 7
Berobenatide PF-08653944, MET097PfizerPhase 3Dec 19, 202516 open of 22
ZovaglutideBeijing QL BiopharmaceuticalPhase 3Jan 16, 20266 open of 8
MDR-001MindRank AIPhase 3Feb 1, 20262 open of 4
NNC0487-0111Novo NordiskPhase 3Feb 24, 202613 open of 21
Enicepatide CT-388, RG6640Carmot TherapeuticsPhase 3Mar 16, 20263 open of 6
Tradipitant VLY-686Vanda PharmaceuticalsPhase 3Mar 27, 20261 open of 2
DA-302168SChendu DIAO Pharmaceutical GroupPhase 3Jun 19, 20262 open of 5
Elecoglipron AZD5004, ECC5004AstraZeneca Pharmaceuticals LPPhase 3Jun 29, 20263 open of 11
AleniglipronGasherbrum BioPhase 3Jul 13, 20262 open of 4
Lenbelintide AZD6234AstraZeneca Pharmaceuticals LPPhase 3Aug 19, 20266 open of 12
ASC30Ascletis Pharma (China)Phase 3Aug 28, 20262 open of 3
ZenagamtideNovo NordiskPhase 3Aug 31, 20266 open of 6
MWN109Shanghai Minwei BiotechnologyPhase 3Sep 1, 20264 open of 8
UBT251The United Bio-Technology (Hengqin)Phase 3Sep 4, 20265 open of 5
BGM0504BrightGene Bio-Medical TechnologyPhase 3Sep 17, 20262 open of 9
Petrelintide ZP8396, RO7895515Zealand PharmaPhase 3Sep 30, 20263 open of 8
ALN-CIDEBRegeneron PharmaceuticalsPhase 3Oct 28, 20262 open of 2
JNJ-64565111Janssen Research & DevelopmentPhase 2Mar 26, 20183, none open
Cotadutide MEDI0382MedImmunePhase 2May 8, 20188, none open
CannabidiolRadius PharmsPhase 2May 9, 20182, none open
Tesofensine/MetoprololSanionaPhase 2Feb 25, 20191, none open
Livoletide AZP-531Millendo Therapeutics SASPhase 2Mar 25, 20191, none open
Miricorlilant CORT118335Corcept TherapeuticsPhase 2Dec 4, 20192, none open
Danuglipron PF-06882961PfizerPhase 2Jan 6, 20217, none open
SHR20004Jiangsu Hengrui MedicinePhase 2Mar 29, 20211, none open
IMB-1018972Imbria PharmaceuticalsPhase 2Apr 21, 20211, none open
Efimosfermin BOS-580GlaxoSmithKline LLCPhase 2Sep 30, 20211, none open
MBL949Novartis Pharmaceuticals CorporationPhase 2Feb 10, 20221, none open
CT-868 RO7795074Carmot TherapeuticsPhase 2Feb 22, 20223, none open
HSG4112GlaceumPhase 2Feb 24, 20225, none open
Pemvidutide ALT-801AltimmunePhase 2Mar 31, 20226, none open
RAD011Radius PharmsPhase 2Apr 13, 20221, none open
LadarixinDompé FarmaceuticiPhase 2Sep 14, 20221, none open
RGH-706Gedeon RichterPhase 2Sep 22, 20221, none open
PF-07081532PfizerPhase 2Oct 27, 20225, none open
HU6Rivus PharmaceuticalsPhase 2Oct 30, 20223, none open
APHD-012 APHD-012P, APHD-008Aphaia Pharma USPhase 2Nov 1, 20221 open of 3
10XB-10110xBioPhase 2May 4, 20231, none open
S-309309ShionogiPhase 2Jun 21, 20233, none open
INV-202Inversago PharmaPhase 2Sep 8, 20232, none open
K-757TriGemX BioPhase 2Sep 15, 20232, none open
LY3549492Eli LillyPhase 2Nov 17, 20231 open of 4
Macupatide LY3532226Eli LillyPhase 2Nov 17, 20234 open of 5
Mazdutide LY3305677Eli LillyPhase 2Nov 17, 20231 open of 3
Bivamelagon LB54640Rhythm PharmaceuticalsPhase 2Dec 1, 20231 open of 3
RGT001-075Regor PharmaceuticalsPhase 2Mar 8, 20242, none open
NNC0519-0130Novo NordiskPhase 2Mar 18, 20241 open of 7
GLY-200GlyscendPhase 2May 20, 20241, none open
DD01NeuralyPhase 2Jun 13, 20242, none open
NA-931Biomed IndustriesPhase 2Jul 19, 20241 open of 3
CK-0045Cytoki PharmaPhase 2Sep 6, 20242, none open
ROSE-010Rose PharmaPhase 2Sep 26, 20241, none open
RDX-002Response PharmaceuticalsPhase 2Sep 27, 20241, none open
PF-07976016PfizerPhase 2Dec 9, 20242, none open
IMM01-STEMImmunisPhase 2Dec 19, 20241 open of 1
THDBH120Tonghua Dongbao PharmaceuticalPhase 2Jan 6, 20251 open of 2
VTX3232Zomagen BiosciencesPhase 2Jan 7, 20251, none open
KBP-336KeyBiosciencePhase 2Jan 28, 20251 open of 1
TERN-601TernsPhase 2Mar 7, 20251, none open
LY3457263Eli LillyPhase 2Mar 28, 20251 open of 2
RO7204239 GYM329Hoffmann-La RochePhase 2May 5, 20252 open of 2
NT-0796NodTheraPhase 2May 8, 20253, none open
EMP16-02Empros Pharma ABPhase 2May 20, 20251 open of 2
GV101Graviton BiosciencePhase 2Jun 30, 20251, none open
KDS2010NeuroBiogenPhase 2Jul 29, 20251 open of 1
Tifeglipron RO7795081, CT-996Hoffmann-La RochePhase 2Jul 29, 20252 open of 4
MKP10241Mankind PharmaPhase 2Aug 12, 20251 open of 1
MWN105Shanghai Minwei BiotechnologyPhase 2Sep 3, 20251 open of 3
NNC0662-0419Novo NordiskPhase 2Oct 1, 20253 open of 5
S1B-509S1 BiopharmaPhase 2Oct 15, 20251 open of 1
Taldefgrobep Alfa BHV-2000Biohaven TherapeuticsPhase 2Nov 24, 20251 open of 1
VRB-101Verdiva Bio Dev LimitedPhase 2Nov 25, 20251 open of 3
HM15275Hanmi Pharmaceutical Company LimitedPhase 2Dec 2, 20251 open of 2
ZT006Beijing QL BiopharmaceuticalPhase 2Dec 12, 20251 open of 2
BMB-101Bright Minds Biosciences PtyPhase 2Jan 1, 20261 open of 1
GL0034Sun Pharmaceutical IndustriesPhase 2Jan 20, 20261 open of 1
MOTS-cHudson BiotechPhase 2Feb 2, 20261 open of 1
KAI-7535KaileraPhase 2Apr 6, 20261 open of 2
PF-08653945PfizerPhase 2May 11, 20262 open of 2
CSTI-500 AMR-001181ConSynance TherapeuticsPhase 2May 18, 20261 open of 2
ERX1000ERX PharmaceuticalsPhase 2May 28, 20261 open of 2
Alirocumab REGN727, SAR236553Regeneron PharmaceuticalsPhase 2Jun 17, 20261 open of 1
AT673Antag TherapeuticsPhase 2Jun 19, 20261 open of 1
BI 3034701Boehringer Ingelheim Pharmaceuticals, Inc.Phase 2Jun 30, 20263 open of 5
HRS-4729Fujian Shengdi PharmaceuticalPhase 2Jul 1, 20262 open of 3
ABBV-295AbbViePhase 2Aug 4, 20263 open of 4
ALV-100Alveus TherapeuticsPhase 2Aug 10, 20262 open of 2
Clazakizumab LY5724886Eli LillyPhase 2Aug 27, 20261 open of 1
SYH2069CSPC Ouyi PharmaceuticalPhase 2Sep 1, 20262 open of 2
TE-8105ImmunworkPhase 2Oct 1, 20261 open of 2
Investigational product is a…EktaHPhase 2Oct 20, 20261 open of 1
LY4086940Eli LillyPhase 2Nov 1, 20261 open of 2

Company-sponsored phase 1 to 3 trials whose conditions include obesity or overweight and that started in 2018 or later; withdrawn trials and placebo arms are left out. A drug used only as a comparator in another company's trial is not counted as that company's program. A phase 1/2 trial counts as phase 1. Phases run in other conditions (such as diabetes) or before 2018 are not shown. FDA approvals are the first approval of each obesity brand in Drugs@FDA (Wegovy, Zepbound, Saxenda, Imcivree, Foundayo). Refreshed daily. ClinicalTrials.gov · Updated Nov 13, 2026

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.